Spondyloarthritis & psoriatic arthritis
Treating spondyloarthritis early: does it matter? Results from a systematic literature review
Authors' conclusion
Evidence towards better outcomes in early axSpA is very limited and restricted to non-radiographic axSpA and <5 years symptom duration. When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found.
Study context
- Population
- Patients with SpA treated with NSAIDs or b/tsDMARDs; all included studies in axial SpA (axSpA)25 included + 2 by hand-search, all axSpA
- Comparison
- Early vs later treatment in SpA treated with NSAIDs or b/tsDMARDs
- Outcome
- Treatment response assessed by any disease activity outcome
Methodological details8769 articles retrieved; 25 included plus 2 by hand-search; most with low risk of bias, 21 studies compared by symptom duration (n = 6) or disease duration (n = 15); 7 by absence/presence of radiographic damage
- 8769 articles retrieved; 25 included plus 2 by hand-search; most with low risk of bias
- 21 studies compared by symptom duration (n = 6) or disease duration (n = 15); 7 by absence/presence of radiographic damage
Main finding
As reported in the abstract
ASAS40, early (symptom duration <5 years) vs later treatment, nr-axSpA RCTs (n = 2)
Early axSpA vs Later axSpARelative risk ratio (95% CI)
nr-axSpA, study 1
5.24(1.12–24.41)
nr-axSpA, study 2
1.52(0.60–3.87)
Further findings
| Outcome | Relative risk ratio (CI) | |
|---|---|---|
| ASAS20, early (symptom duration <5 years)vs later treatment, r-axSpA RCT (n = 1) | 0.96 (0.53–1.73) | |
| 0.512Relative risk ratio (log scale) |
Early axSpA defined by disease duration or radiographic damage
- No differences were found between groups
Original publication
Treating spondyloarthritis early: does it matter? Results from a systematic literature review. Rheumatology (Oxford). Published 13 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →